1 completed, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Relapsing Multiple Sclerosis (RMS): new trials by email Literature Review of Relapsing Multiple Sclerosis (RMS) trials Research Report on Relapsing Multiple Sclerosis (RMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Effects of Cladribine Tablets on the PK of Microgynon® Cladribine, Placebo, Microgynon® - Relapsing Multiple Sclerosis (RMS) | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 28 | 2019-01-17 | 2024-03-15 |
Multiple Sclerosis (2) · Autoimmune Diseases (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Autoimmune Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cladribine (1) · ethinyl estradiol, levonorgestrel drug combination (1)
Cabaletta Bio (1) · Merck KGaA, Darmstadt, Germany (1)
Germany (1) · Poland (1)
2018 (1)